🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — March 06, 2026

Overnight SEC filings (92 total) for March 5-6, 2026 reveal mixed FY2025 results across sectors, with average revenue growth of ~20% YoY in 25+ reporting companies (e.g., Chime +31%, Via +29%, Pattern +39%) offset by profitability challenges including widened losses (avg net loss expansion 15-30% in biotechs/REITs) and margin compression (-100bps avg in retail/energy). Energy/oil shows weakness (BP revenues flat, production -12% YoY; Granite Ridge NOI -22%), while fintech/SaaS outperforms on top-line (Guidewire +25%, MarketWise billings +13.5%) but faces expense pressures. REITs mixed with NOI growth in some (Unknown #10 +12.1%) but declines (Ares -2.1% same-store); BDCs/credit funds stable NAV/distributions. SPAC activity surges with IPOs (APEX $112M), extensions (Crown PropTech EGM Mar9), and combos (ReserveOne, Willow Lane). Capital allocation leans shareholder-friendly (MarketWise +25% dividend, resume $50M buyback; News Corp $1B repurchase), but debt raises proliferate (Waste Connections notes, Dave $175M conv notes). Key implications: Near-term catalysts from 10+ deal closings/meetings drive volatility; watch REIT/energy for impairments amid high debt trends.

59 high priority 33 medium 92 total filings
· daily

Federal Construction & Infrastructure Contracts — March 05, 2026

Three federal infrastructure contracts totaling $543.8M signal robust DOI ($436.4M) and DOT spending on long-term construction projects, with $139.7M already outlayed securing near-term cash flows. All firm-fixed-price awards to construction firms highlight revenue visibility through 2029 but embed execution risks from cost overruns. Investors should prioritize DOI-aligned contractors for multi-year backlog growth amid steady federal outlays.

3 total filings
· daily

Federal Professional Services Contracts — March 05, 2026

Two large federal professional services contracts totaling $385M in obligations signal bullish revenue visibility for RTX (via Raytheon) and Ball Corp (via BAE Systems) through 2025-2026. Raytheon's $217M FAA sustainment order shows strong execution with 95% outlay ($206M), while BAE's $169M FBI BPA has $183M in unobligated options despite zero outlays to date. Investors should prioritize monitoring option exercises and outlay ramps for multi-year tailwinds in engineering and consulting services.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — March 05, 2026

Dell Federal Systems secured a $107.7M obligated BPA call (up to $182.7M with options) from NIH for enterprise software licenses, with $71M already outlayed, signaling strong federal health IT demand and multi-year revenue for Dell. This single large award underscores Dell's entrenched position in government software procurement amid full and open competition. Investors should monitor option exercises for an additional ~$75M upside, balanced against firm fixed-price execution risks.

1 total filings
· daily

New Federal Contractors — March 05, 2026

This period's $1.88B in new federal contract obligations signal strong U.S. government commitment to long-term infrastructure, space, healthcare admin, and aviation sustainment projects, all with bullish implications for recipients. Ball Corp gains outsized exposure via two BAE subsidiaries ($644M total), while construction firms secure ~$54% of value amid multi-year builds to 2029. Unexercised options exceed $400M across deals, offering upside, but firm-fixed-price dominance (~60% of contracts) heightens cost overrun risks in inflationary environment.

8 total filings
· daily

Significant Contract Modifications ($10M+) — March 05, 2026

Nine significant contract modifications totaling $1.88B signal robust U.S. government spending, with 8 bullish awards dominated by space/defense ($1.07B, 57%), infrastructure construction ($544M, 29%), and healthcare/IT ($477M, 25%). Ball Corporation gains outsized exposure via two BAE subsidiaries ($645M combined), while construction firms face firm-fixed-price risks amid long tenors (avg. 5+ years). Unexercised options exceed $400M across deals, offering near-term upside if funded.

9 total filings
· daily

Contract Deobligations Alert — March 05, 2026

Nine contract records totaling $1.88B in obligations signal bullish revenue stability for defense/space (BAE/Ball Corp, RTX/Raytheon), healthcare (Wisconsin Physicians, Dell), and infrastructure firms (TEPA, Kiewit, Maymead), with performance periods extending to 2029 and $1.1B+ remaining outlay potential. Unexercised options exceed $400M across deals, offering near-term upside amid low outlays on some awards. Single neutral signal on minor Lockheed deal underscores focus on high-value, multi-year commitments from NASA, HHS, Interior, and DOT.

9 total filings
· daily

Contract Option Exercises — March 05, 2026

This period's $1.88B in contract option exercises signals robust U.S. government spending, with 8/9 bullish awards dominated by long-term commitments in space/defense ($661M across BAE and Raytheon), infrastructure construction ($544M), and healthcare administration ($369M from Wisconsin Physicians). Ball Corporation subsidiaries capture 2 of top 6 awards totaling $645M, underscoring defense stability through 2029. Construction firms face elevated firm-fixed-price risks amid multi-year timelines to 2029, while unexercised options exceed $400M across records.

9 total filings
· daily

All HHS Contracts — March 05, 2026

HHS awarded two major contracts totaling $476.9M obligated value in this period, signaling robust federal demand for Medicare administration and NIH software licensing with multi-year revenue visibility through 2028. Both awards to established players (Wisconsin Physicians Service and Dell Federal) show $322.1M already outlayed, underscoring execution momentum amid $149.2M in unexercised options. Investors gain bullish exposure to healthcare services and federal IT via cost-plus and firm-fixed structures.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 05, 2026

Eight mega contracts totaling $1.88B awarded across space/defense, health services, and infrastructure sectors signal robust federal spending with long-term revenue visibility through 2029. Ball Corp subsidiaries (BAE entities) capture $645M (34% of total), underscoring defense/space strength, while construction firms secure $544M (29%) amid infrastructure push. All bullish with average 7+ year durations and $926M (49%) already outlayed, but firm-fixed-price structures and unexercised options (~$500M aggregate upside) warrant monitoring execution.

8 total filings
· daily

High-Value Federal Grants ($5M+) — March 05, 2026

Eight high-value federal contracts totaling $1.88B signal robust government spending, providing multi-year revenue visibility through 2029 for winners in space/defense, healthcare administration, and infrastructure. Ball Corporation benefits doubly via BAE subsidiaries ($644.9M combined), while infrastructure firms secure $641.8M in firm-fixed projects amid extended timelines. All bullish signals highlight stable outlays ($926.8M already disbursed across portfolio) but flag execution risks in firm-fixed structures and unexercised options (~$560M potential).

8 total filings
· daily

General Federal Contracts — March 05, 2026

Eight bullish federal contracts totaling $1.88B highlight robust U.S. government demand for space/defense, healthcare administration, and infrastructure construction, with multi-year performance periods extending to 2029 providing revenue stability for key contractors. BAE Systems (Ball Corp parent) captures 2 contracts worth $645M, underscoring defense/space exposure, while construction awards exceed $540M across 3 deals. Unexercised options exceed $400M, signaling near-term upside amid firm-fixed-price and cost-plus structures.

8 total filings
· daily

All NASA Contracts — March 05, 2026

A single $476M NASA contract awarded to BAE Systems Space & Mission Systems Inc. (Ball Corp subsidiary) underscores stable long-term revenue in space vehicle components through 2029, with $141M already outlayed and $336M remaining. This non-competitive, cost-plus-award-fee deal signals bullish commitment to OMPS program engineering but carries execution risks from its 19-year duration and $23M subawards. Investors should prioritize monitoring outlays and performance fees for revenue visibility.

1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 05, 2026

Across 50 filings from the S&P 500 Consumer Staples stream and adjacent sectors, sentiment is predominantly mixed (18/50 filings), reflecting resilient top-line growth in staples/wholesale leaders like Costco (+9.1% YoY Q2 sales, +7.4% comps) and BJ's (+4.6% FY sales, +9.5% membership fees) offset by softness elsewhere (Kroger FY sales flat YoY, Clarus FY sales -5.3% YoY). Period-over-period trends show average revenue growth of ~+5% YoY in reporting consumer firms (e.g., 6/12 with sales data >+4% YoY) but margin compression in 7/12 (avg -100 bps, e.g., Clarus gross margin -190 bps, Kroger OG&A +29 bps FY), impairments rampant (10+ filings, e.g., Kroger $2.5B, Lineage $14.8M), and narrowing losses in turnarounds (flyExclusive net loss -34% YoY). Capital allocation tilts shareholder-friendly with buybacks (Kroger $7.5B completed +$2B approved, BJ's $117.7M Q4) and dividend hikes (Philip Morris to $1.47, Korn Ferry +14.6% to $0.55), while financing ramps for liquidity (Pulmonx $60M facility, Vivakor $750k note amid distress). Forward-looking signals mixed: upbeat guidance (Clarus 2026 sales +2-6% YoY, EBITDA to $9-11M), but narrows (Methode FY26 sales $950M-1B). Portfolio-level: staples show defensive comp sales (+1-7% YoY avg), but broader distress in non-core (Monroe Capital NII -53% YoY). Critical implications: favor wholesale staples for stability, monitor impairments/debt for staples-adjacent risks.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 05, 2026

Across 92 SEC filings from the USA S&P 500 Industrials intelligence stream (including energy services, transportation, machinery, and adjacent sectors like aerospace/defense), mixed sentiment prevails in 70% of cases, reflecting revenue growth in production-heavy firms (avg +15% YoY in energy/oil like Granite Ridge +27%, SandRidge +12%) offset by service declines (Ranger Energy -4% FY revenue) and margin compression (avg -50 bps where reported). Period-over-period trends show improving net losses in 40% of biotechs/pharmas (e.g., Gevo -57%, Lexicon -75%) but widening in others (EyePoint +77%), with capital allocation favoring dividends/buybacks (Kroger $7.5B repurchases, Ranger $42.9M FCF to returns >40%). M&A/SPAC activity surges (Pasqal $2B Bleichroeder merger H2 2026, Home Bancshares MCBI Q2 2026), alongside leadership churn in transportation (Delta exec promotions). Forward-looking guidance clusters around modest 2026 growth (Granite Ridge +9%, Traeger flat revenues), building a catalyst calendar heavy in Q2 trial data/FDA meetings. Portfolio-level, Industrials exhibit resilient production amid pricing pressures, signaling selective upside in energy services/transport but risks from impairments/debt.

55 high priority 37 medium 92 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 05, 2026

The sole filing in the USA S&P 500 Energy intelligence stream is an 8-K from Copper Property CTL Pass Through Trust, announcing a monthly cash distribution of $0.082844 per trust certificate, payable on March 10, 2026, to holders of record on March 9, 2026. This reflects positive sentiment (rated positive) and steady capital allocation focused on shareholder returns via distributions, with materiality at 6/10. No period-over-period comparisons, YoY/QoQ trends, insider trading activity, forward-looking guidance, M&A details, financial ratios, or operational metrics were disclosed in the filing, limiting quantitative trend analysis across the sector. The availability of the monthly report for the period ending February 28, 2026, on the investor website (www.ctltrust.net) enhances transparency. Key implication: This signals reliable income generation in the energy sector trust space, potentially appealing to yield-seeking investors amid stable cash flows, though absence of comparative data prevents identifying growth or margin trends at a portfolio level.

1 medium 1 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 05, 2026

Across the 416 pre-analyzed SEC filings from S&P 500 Financials and adjacent sectors (though data skews to energy, biotech, retail, and industrials), overarching themes include mixed FY2025 results with revenue growth in 62% of reporting companies (avg +12% YoY) offset by margin compression in 58% (avg -85 bps YoY), driven by higher operating costs and impairments; capital allocation favors buybacks/dividends in 28 companies (e.g., $7.5B Kroger repurchase completed, $2B authorized). Insider activity shows neutral conviction with appointments dominant (e.g., 15 new directors/CFOs) but few buys/sells. Forward-looking guidance is cautious with 45% raising revenue targets (avg +10%) but 32% trimming EBITDA/margins amid economic pressures. M&A accelerates (12 deals, avg $500M+ valuation, e.g., USA Rare Earth $73M acquisition), signaling consolidation. Portfolio-level trends: EBITDA flat/declining in 55% despite revenue beats, highlighting cost inflation; energy/biotech outliers with 20-50% YoY declines in key metrics. Implications: Favor resilient dividend payers and M&A targets; avoid margin squeezes in retail/energy.

227 high priority 189 medium 416 total filings
· daily

US Material Events SEC 8-K Filings — March 05, 2026

Across 84 SEC filings from March 5, 2026, dominant themes include widespread executive churn (25+ filings on appointments/departures, especially CFO/CAO roles like Sysco/McKesson swaps, Trulieve termination), robust M&A/divestiture activity (e.g., rare earth consolidation via USA Rare Earth/TMRC $73M deal, Six Flags $331M park sale), and financing enhancements (20+ credit amendments/extensions like RPM to 2031, Simon $5B rev revolver). Period-over-period trends show mixed revenue performance: growth in OptimizeRx FY2025 +19% YoY to $109.4M, Full House FY2025 +3.5% to $302.4M, Camp4 cash +71% to $109.5M, but declines in GoPro FY2025 -19% to $652M and hardware -21.5%; margins compressed in GoPro -290bps Q4 to 31.8%, flat EBITDA in Full House. Capital allocation leans shareholder-friendly with EPAM $300M ASR (remaining $452.5M program), OptimizeRx $10M buyback, AZZ board refresh for M&A/ESG. Critical implications: Positive for rare earths/tech consolidation amid supply chain risks, caution on media distress (Cumulus Ch11) and cannabis/consumer volatility; portfolio-level alpha in financing-secured growth names vs. restructuring risks.

84 high priority 84 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 05, 2026

Across 20 SEC filings from diverse sectors mislabeled under S&P 500 Technology stream, dominant themes include robust revenue growth in 9/20 companies (avg +35% YoY where quantified, e.g., Evommune +86%, Entravision +23%, CrowdStrike +22%) offset by widening net losses in 10/20 (e.g., CrowdStrike loss to $162.5M, Entravision to $79.2M) due to surging OpEx (avg +25% YoY). Mixed sentiment prevails (12/20 filings), with positive catalysts like biotech trials (Altimmune Q3 2026 RECLAIM data, Evommune 2Q/2H26 Phase 2b), capital allocation via dividends (Iridium $0.15/share, Entravision $0.20), M&A/divestitures (CYH $112M hospital sale Q2 2026 close, Genco vessel acquisition), and restructurings (Cumulus prepackaged Ch.11). Margin compressions hit 7/15 with data (avg -100bps, e.g., NCS services to 45%, Weave onboarding -153%), while cash positions strengthened in biotechs (Altimmune +107% YoY to $274M, Evommune to $216.7M). Insider activity limited to appointments (Acadia new director, Altimmune CEO change), no major buys/sells. Portfolio implications: Bullish on turnaround growth (Adial loss -40% YoY), bearish on bankruptcy risks (Cumulus); monitor Q2 2026 catalysts for alpha in undervalued assets.

14 high priority 6 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 05, 2026

Across 22 NASDAQ-100 filings, mixed sentiment prevails with 12/15 annual reports showing average revenue growth of 25% YoY (range +9% Costco to +86% Evommune) driven by tech/services/advertising segments, but offset by profitability pressures including widened losses (e.g., +3% Evommune, +12% Metagenomi), impairments (Entravision $55M), and margin declines (NCS services 45% vs 49%). Biotech cluster (Altimmune, Evommune, Metagenomi, Adial) highlights pipeline catalysts and cash runways to 2027-28 despite revenue volatility (-52% Metagenomi). Media/comms face headwinds (Cumulus bankruptcy prep, Entravision media -20-32% YoY), while retail (Costco +9% sales) and shipping (Genco acquisition) shine. Capital allocation steady with dividends (Iridium $0.15, Entravision $0.20 unchanged), reverse split (Aditxt 1:8), and M&A (CYH $112M sale Q2 2026). Portfolio implications: Favor consumer/biotech catalysts, avoid distressed media, monitor restructuring votes/debt closes for near-term volatility.

15 high priority 7 medium 22 total filings